Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed renal cell carcinoma (RCC) of clear cell histology with or without sarcomatoid features
• * Metastatic disease
• * No non-clear cell RCC (i.e., papillary, collecting-duct, or chromophobe)
• Good- or intermediate-risk category as defined by having ≤ 2 of the following factors:
• * No prior nephrectomy
• * Karnofsky performance status \< 80%
• * Hemoglobin \< 12 g/dL
• * Corrected calcium \> 10.0 mg/dL
• * LDH \> 1.5 times upper limit of normal (ULN)
• Must have undergone a nephrectomy at least 28 days ago
• Measurable or evaluable disease by RECIST
• No significant effusions and/or ascites
• No prior or concurrent brain or CNS metastasis
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-1
• Life expectancy of ≥ 3 months
• WBC ≥ 3,000/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9.5 g/dL
• Creatinine ≤ 2.0 mg/dL
• Total bilirubin ≤ 1.5 mg/dL
• AST ≤ 5.0 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN (≤ 10 times ULN with bone metastasis)
• Calcium ≤ 12 mg/dL
• Urine protein:creatinine ratio ≤ 1.0
• INR ≤ 1.5 (unless receiving warfarin therapy)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No uncontrolled seizure disorder
• No known HIV positivity
• No local or systemic infections requiring IV antibiotics within the past 28 days
• No significant traumatic injury in the past 28 days
• No serious non-healing wound, ulcer, or acute bone fracture
• No evidence of bleeding diathesis or coagulopathy
• No other malignancy except basal cell or squamous cell carcinoma of the skin, carcinoma in-situ of the uterine cervix, or any malignancy treated with curative intent and in complete remission for \> 3 years
• No history of serious systemic or severe cardiovascular disease, including any of the following:
• * Arterial thromboembolic event (including transient ischemic attack)
• * Cerebrovascular accident
• * Unstable angina
• * Myocardial infarction within the past 6 months
• * Uncontrolled hypertension (BP \> 160/110 mm Hg on medication)
• * Uncontrolled cardiac arrhythmia
• * Congestive heart failure
• * Angina pectoris
• * NYHA class III-IV cardiovascular disease
• * Peripheral vascular disease ≥ grade II
• No history of abdominal fistula and/or bowel or gastric perforation within the past 6 months
• No history of other diseases, metabolic dysfunction, or physical or laboratory examination findings giving reasonable suspicion of a disease or condition that contraindicate the use of investigational drugs, or that might affect the interpretation of study results, or that render patient at high-risk for treatment complications
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior organ allografts
• No prior systemic therapy for metastatic clear cell renal cell carcinoma
• At least 4 weeks since prior radiotherapy and recovered
• * Radiotherapy for control of pain from skeletal lesions allowed within the past 28 days
• More than 12 months since prior adjuvant therapy
• More than 7 days since prior fine-needle aspirations or core biopsies
• More than 28 days since prior and no concurrent major surgery requiring general anesthesia or open biopsy
• No concurrent aspirin, corticosteroids (except at replacement doses), barbiturates, or other investigational agents